What is the most appropriate frequency of injections during Bortezomib treatment?

Bortezomib is a commonly used proteasome inhibitor widely used in the treatment of multiple myeloma and certain lymphomas. The dosing frequency and regimen need to be adjusted according to the patient's specific condition, treatment stage and tolerance. Generally, bortezomib is administered twice a week or once a week.

The traditional treatment regimen is usually twice a week, and the common administration times are 1, 4, 8, 11 days, and every 21 days constitutes a cycle. The advantage of this arrangement is that it can better control tumor cells while giving the patient a certain amount of time to recover, which is beneficial to reducing the side effects of the drug, such as neurotoxicity and blood suppression. Many clinical trials and practical experience support this regimen as the standard choice for initial treatment.

In recent years, in order to reduce side effects and improve patients' quality of life, more and more doctors have adopted weekly dosing regimens. Studies have shown that once-weekly bortezomib is nearly as effective as twice-weekly administration, but with significantly fewer side effects, particularly a lower incidence of neuropathy. This regimen is suitable for patients with poor tolerance or elderly patients, or for use during the maintenance treatment phase.

In short, the dosage frequency of bortezomib should be flexibly adjusted based on the patient's illness and physical condition. Patients who are new to treatment usually adopt a twice-weekly regimen to achieve the best effect. Once-weekly treatment may be considered if the patient has poor tolerance or maintenance treatment. No matter which plan is chosen, patients should undergo regular monitoring under the guidance of a professional doctor and handle adverse reactions in a timely manner to ensure treatment safety and maximum effectiveness.

Reference materials:https://www.drugs.com/donanemab.html